Company profile for Nanjing Impact BioScience Ltd

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Nanjing Impact BioScience Ltd (NIBS) is an emerging biopharmaceutical company specialized in peptide synthesis and peptide drug research and development. NIBS is dedicated to providing high quality and cost-effective custom peptide synthesis and manufacturing service and custom antibody services to satisfy our clients' outsourcing needs. In addition, we are able to offer an extensive range of catalogue peptides and a wide rang...
Nanjing Impact BioScience Ltd (NIBS) is an emerging biopharmaceutical company specialized in peptide synthesis and peptide drug research and development. NIBS is dedicated to providing high quality and cost-effective custom peptide synthesis and manufacturing service and custom antibody services to satisfy our clients' outsourcing needs. In addition, we are able to offer an extensive range of catalogue peptides and a wide range of reagents used for the synthesis of peptides. Our mission is to advance our customers' research efficiency, enhance their core competitiveness and ultimately improve their research productivity.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
No.10 Xinghuo Road
Telephone
Telephone
86 025 858 48600
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

BPI Europe

BPI Europe

Not Confirmed

envelop Contact Supplier

BPI Europe

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Pharma shells out $100B on M&A in 2018 so far: report
Pharma shells out $100B on M&A in 2018 so far: report

06 Jul 2018

// Arlene Weintraub FIERCE PHARMA

https://www.fiercepharma.com/pharma-shells-out-100b-m-a-2018-so-far-more-to-come-report

Arlene Weintraub FIERCE PHARMA
06 Jul 2018

https://www.biospace.com/article/more-than-100-billion-spent-on-m-and-a-in-the-first-6-months-of-2018/

Karl Thiel BIOSPACE
05 Jul 2018
Just a Little Patience: In-licensing from Biopharma
Just a Little Patience: In-licensing from Biopharma

20 Mar 2018

//  Samantha Truex LIFESCIVC

https://lifescivc.com/2018/03/just-a-little-patience-in-licensing-from-biopharma/

 Samantha Truex LIFESCIVC
20 Mar 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty